FRANKFURT: German biotech CureVac said on Friday it had filed for an initial public offering in the United States as it races to develop a vaccine for Covid-19. The company, valued at around $1.6 billion and backed by Microsoft Corp co-founder Bill Gates whose foundation has been a shareholder and provided grants, started its clinical study in healthy volunteers in June.
Results of the safety-focused trial are expected in the fourth quarter of 2020, regulatory filings showed. It previously had said approval was possible in the middle of next year, under favourable conditions.
Comments
Comments are closed.